Major Middle East Expansion: Cosmos Health Lands Exclusive $578K Qatar Distribution Contract

Posted by author February 6, 2025 World

Spread the love

Cosmos Health (NASDAQ:COSM) has received an initial purchase order worth $578,460 from Al Rabwa International Services and Trading for its Sky Premium Life® food supplement products in Qatar. The order encompasses 35 of the Company’s 79 SKUs, with Al Rabwa receiving exclusivity rights for distribution.

Al Rabwa, established in 2013, has grown into a leading distribution company in Qatar, serving retail, food service, and wholesale sectors. The company maintains a broad product portfolio supported by global suppliers and producers, along with professional sales, marketing, and customer service operations.

Positive

Secured significant initial purchase order of $578,460

Obtained exclusive distribution agreement in Qatar market

Order covers 44% of company’s SKUs (35 out of 79 products)

Partnership with established distributor provides access to retail, food service, and wholesale sectors

Insights

The $578,460 purchase order represents a significant development for Cosmos Health, constituting approximately 3.6% of its current market capitalization. The deal’s structure reveals several strategic advantages:

The initial order covering 44% of available SKUs (35 out of 79) suggests a measured approach with room for expansion, indicating potential for future order growth
Securing exclusivity rights in Qatar creates a protected market position and recurring revenue potential
Partnership with Al Rabwa, a well-established distributor, provides immediate access to multiple distribution channels

Qatar’s nutraceutical market is particularly attractive due to high disposable income levels and increasing health consciousness among consumers. The country’s population, though relatively small at 2.9 million, has one of the highest GDP per capita globally, suggesting strong purchasing power for premium health products.

For a micro-cap company like Cosmos Health, this deal represents a meaningful revenue catalyst. The exclusivity arrangement, while limiting alternative distribution options, provides a foundation for building brand presence in the Gulf region. The order size indicates Al Rabwa’s confidence in market demand, though investors should monitor subsequent orders to gauge market traction and growth trajectory.

02/06/2025 – 03:50 PM

CHICAGO, IL / ACCESS Newswire / February 6, 2025 / Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received an initial purchase order of $578,460 from Al Rabwa International Services and Trading (“Al Rabwa”) for its Sky Premium Life® food supplement products in Qatar.

The initial purchase order covers 35 of the Company’s 79 SKUs. Al Rabwa has been granted exclusivity, and the Company looks forward to strengthening this partnership through additional future orders.

Established in 2013, Al Rabwa has successfully evolved into one of the leading distribution companies in Qatar, catering to retail, food service, and wholesale sectors. Al Rabwa’s extensive product portfolio is backed by a network of reputable global suppliers and producers, complemented by a professional, world-class approach to sales, marketing, and customer service – giving the company a leading edge in Qatar’s distribution space.

Greg Siokas, CEO of Cosmos Health, stated: “We are delighted to announce our first order from Al Rabwa, allowing us to capitalize on Qatar’s rapidly expanding market. This is another important partnership for Cosmos and a testament to the high quality of our products and the strong global demand they continue to attract.”

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could”, are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company’s business, operations and the economy in general, and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653

SOURCE: Cosmos Health Inc.

View the original press release on ACCESS Newswire